Pre Transplantation Melanoma

Completed

• Conditions: Malignant Melanoma

• Registration Number: NCT04217382
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Melanoma incidence is increase in global population and number of transplantation also. However immunosuppressor increase recurrence risk of melanoma.

There are more and more cases of eligible patients to transplant with an antecedent of melanoma. There is no guideline yet.

Main objective is survival time without melanoma recurrence in this population to do guideline of time limit or not between melanoma and transplantation by stage.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-12-30
• Study First Submitted QC: 2020-01-02
• Study First Posted: 2020-01-03
• Study Start: 2020-02-27
• Primary Completion: 2020-08-31
• Study Completion: 2020-08-31
• Status Verified: 2021-12
• Last Update Submitted: 2021-12-09
• Last Update Posted: 2021-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• patient with an antecedent of melanoma before transplantation
• Not opposite to participate

Exclusion Criteria

• Under the age of 18
• patient under Guardianship
• patient not affiliated with a health system

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
survival time without melanoma recurrence	at enrollment	Delay in recurrence-free survival since diagnosis and since transplantation

Trial Locations

Locations (1)

service de dermatologie - hopital Edouard Herriot; 🇫🇷 Lyon, Rhone, France